Autologus serum in treatment of dry eye disorder: An evaluation



Similar documents
Treating the Eye with Autologous and Allogeneic Serum Administration. Clarke D. Newman, OD, FAAO

A Life that is born makes Life Grow. programmes

There Are Millions of People at Risk For Dry Eye Who Is Likely to Develop This Irritating Condition?

Ocular Surface Syndrome after LASIK

Grading staining: Oxford Schema The scheme is used to estimate surface damage in dry eye.

WHAT TO DO IF YOU HAVE DRY EYES...

C Diagnosis and Management of Dry Eyes Part 1. Dr Colm McAlinden, BSc (Hons), MSc, PhD and Dr Eirini Skiadaresi, MD.

Managing Post-Operative Complications for LASIK and PRK

A normal eye is protected by a layer of natural tears.

Acknowledgements. Dry Eye Update. Dry Eye. Dry Eye. Dry Eye Monterey Symposium

Lacrimal gland. Tear duct into nose

The Definition & Classification of Dry Eye Disease

Dry Eye: Natural History, Diagnosis and Treatment By Jeffrey P. Gilbard, M.D.

Hypromellose Eye Drops BP 0.3% w/v PL 23097/0006

Eye Manifestations of Lupus And Sjogren s Syndrome

DRY EYE & Carboxymethyl Cellulose

Autologous serum for ocular surface diseases

REFRACTIVE SURGERY NIGHTMARES Dr.ATHIYA AGARWAL

Diagnosing dry eye: It s now a fine art

SF-DCT INFORMATION FOR PRIMARY SJOGREN S SYNDROME (PSS) CLAIMS OPTION 1. (PSS claims are not eligible for Disease Option 2)

U.S. Food and Drug Administration

Thyroid Eye Disease. Anatomy: There are 6 muscles that move your eye.

VITAMIN C AND INFECTIOUS DISEASE: A REVIEW OF THE LITERATURE AND THE RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PROSPECTIVE STUDY OVER 8 YEARS

The conjunctiva in corneal epithelial wound healing

Dry Eye After Clear Cornea Phacoemulsification

AUTOGENEIC SERUM EYE DROPS

Autologous serum eye drops for dry eye (Review)

Laser-Assisted In Situ Keratomileusis for Patients With Dry Eye

Management of Dry Eyes in primary care

OPHTHALMOLOGIST PERCEPTIONS REGARDING TREATMENT OF MODERATE TO SEVERE DRY EYE: RESULTS OF A PHYSICIAN SURVEY

Vitreomacular Traction: What s the Role of the Vitreoretinal Interface in this Disease?

Dry eyes holding you back? Ask your doctor about LipiFlow.

Corneal Collagen Cross-Linking (CXL) With Riboflavin

Basic Considerations in the Diagnosis and Treatment of Iatrogenic Dry Eye Secondary to Vision Correction by Laser Surgery

Complications of Combined Topography-Guided Photorefractive Keratectomy and Corneal Collagen Crosslinking in Keratoconus

Class Im MD A novel device for Automated Analysis of Tear Film Dynamics. Michael Ring, DI(FH) Upper Austria University of Applied Sciences

Limbal Stem Cell Transplantation By C. Michael Samson, MD

Filamentary Keratitis: A Case Series

Ocular Surface Diseases Course 2016 MIAMI,FLORIDA. Bascom Palmer Eye Institute. Sponsored by the University of Miami Miller School of Medicine

Rheumatoid arthritis: an overview. Christine Pham MD

INFORMED CONSENT FOR LASIK SURGERY

Urinalysis and Body Fluids CRg. Synovial Fluid. Synovial Fluid. Unit 4. Composition and formation. Functions. Reasons for analysis.

ZOVIRAX Cold Sore Cream

Focus on Preventing Disease. keeping an eye on a healthy bottom line. Cattle Industry

Failure of the ocular surface epithelia occurs in many clinical

Comparative Evaluation of Dry Eye Following Cataract Surgery: A Study from North India

Postrefractive surgery dry eye Guilherme G. Quinto, Walter Camacho and Ashley Behrens

VOLTAREN OPHTHA EYE DROPS

IDENTIFY DRY EYE AN IN-OFFICE TEST TO AID IN DRY EYE DIAGNOSIS. 85% Sensitivity, 94% Specificity 1. This brochure is for use in Canada only.

MOST FREQUENTLY ASKED CLIENT QUESTIONS

For non-superficial eye injuries an individual may be considered an incident case only once per lifetime.

Keeping Your Eyes Healthy after Treatment for Childhood Cancer

Eye Trauma: Incidence

A survey of eye-related complaints among call-center agents in Metro Manila

Improvement and evaluation of tearscopy potentials

Indolent ulcers in dogs eyes

Thank you in advance- your feedback and insights are invaluable to the BFS team. We really appreciate your ongoing support.

VOLTAREN OPHTHA EYE DROPS

PACKAGE LEAFLET: INFORMATION FOR THE USER. VITAMINE B12 STEROP 1mg/1ml Solution for injection / oral solution. Cyanocobalamin

Prosthetic Replacement of the Ocular Surface Ecosystem PROSE. Information for Patients and Doctors

Institute of Ophthalmology. Thyroid Eye Disease. aka Thyroid Associated Ophthalmopathy

Congratulations! You have just joined the thousands of people who are enjoying the benefits of laser vision correction.

Subcutaneous Testosterone-Anastrozole Therapy in Breast Cancer Survivors ASCO Breast Cancer Symposium Abstract 221 Rebecca L. Glaser M.D.

Proteins. Protein Trivia. Optimizing electrophoresis

The pinnacle of refractive performance.

Aubagio. Aubagio (teriflunomide) Description

Incomplete blinking: Exposure keratopathy, lid wiper epitheliopathy, dry eye, refractive surgery, and dry contact lenses

Vitreo-Retinal and Macular Degeneration Frequently Asked Questions

COPYRIGHTED MATERIAL. What Is Dry Eye Syndrome, and Who Gets It?

FUNCTIONS OF THE SKIN

PATIENT INFORMATION BOOKLET

OVERVIEW OF CALIFORNIA DPA/TPA LAWS

Eye Injuries. The Eyes The eyes are sophisticated organs. They collect light and focus it on the back of the eye, allowing us to see.

FURTHER EXPERIENCE WITH SUBCUTANEOUS IMMUNOGLOBULIN THERAPY IN CHILDREN WITH PRIMARY IMMUNE DEFICIENCIES

The Clinic You see - at Sjonlag Eye Center, we care about your eyes

Flap striae after LASIK can be treated successfully

Use of Nepafenac in Lasek Johnny L. Gayton, MD

Kensington Eye Center 4701 Randolph Road, #G-2 Rockville, MD (301)

Consent for LASIK (Laser In Situ Keratomileusis) Retreatment

Urinalysis and Body Fluids CRg

FULL PRESCRIBING INFORMATION: CONTENTS*

THERAPEUTIC USE OF HEAT AND COLD

Evaluation of Dryness of Eyes after Manual Small Incision Cataract Surgery with Corneoscleral Tunnel Incision

TOTAL PROTEIN FIBRINOGEN

Histology. Epithelial Tissue

Management of Epithelial Ingrowth after LASIK. Helen K. Wu, MD New England Eye Center Tufts University School of Medicine Boston, MA

Summary of the risk management plan (RMP) for Orkambi (lumacaftor and ivacaftor)

Lipid tear deficiency in persistent dry eye after laser in situ keratomileusis and treatment results of new eye-warming device

Some of the ophthalmic surgeries performed at the DMV Center.


1. Contact Lens Solutions 2. Dry Eye Syndrome and Artificial Tears. Dr. Mehdi Alai Optometrist Winnipeg May 2012

Glaucoma. OET: Reading Part A. Reading Sub-test. Complete the following summary using the information in the four texts provided.

Use of a Mini-Scleral Lens for Vision Correction

Cataracts. Cataract and Primary Eye Care Service Main Number Physician Referral AT-WILLS

Teriflunomide is the active metabolite of Leflunomide, a drug employed since 1994 for the treatment of rheumatoid arthritis (Baselt, 2011).

PROSE Treatment Information for Patients and Doctors

How To Treat Eye Problems With A Laser

Vitamin A 10,000 IU Softgels

Changes of Tear Film and Ocular Surface in Diabetes Mellitus

That s a BIG lens!! Scleral Contact Lenses. Average Corneal diameter = 11.5mm. Size matters. Soft Contact Lens 9/24/2014. Average RGP lens = 9.

Transcription:

ISSN: 2231-3354 Received on: 15-05-2012 Revised on: 28-05-2012 Accepted on: 03-06-2012 DOI: 10.7324/JAPS.2012.2627 Autologus serum in treatment of dry eye disorder: An evaluation Rashmi Singh, Ashish Gangwar, Sujata Singh and Braham Dev Sharma ABSTRACT Rashmi Singh, Sujata Singh Department of Pharmacology, Shri Ram Murti Smarak Institute of Medical Sciences,, Bareilly, UP, India. Ashish Gangwar, Braham Dev Sharma Department of Ophthalmology, Shri Ram Murti Smarak Institute of Medical Sciences, Bareilly, UP, India Dry eye syndrome is a common disorder of the tear film in which eye is unable to maintain a healthy layer of tears to coat it. Despite various conventional treatments such as ocular surface lubrication, artificial tears, protective glasses and punctal occlusion many patients continue to have signs and symptoms of dry eye. That s why autologous serum eye drops have been indicated for the treatment of dry eye. Therefore, to evaluate the effectiveness of the autologous serum eye drops in dry eye disorder, a total of 34 eyes of 20 patients were included in this study, who used autologus serum eye drops along with artificial tears. Out of 20 patients, 16 were males and 4 were females with M: F ratio of 4:1. The mean age of the patients was 51.95 years. Evaluations of patients were done before and after treatment in follow up, by determining the subjective and objective scores which showed that after follow up of 2 months all the subjective and objective scores were reduced in 28 eyes but 6 eyes did not show any improvement at follow up of 2 months as they stopped the drops after one month of use because of discomfort. Keywords: Dry eye, autologus serum, subjective and objective scores. INTRODUCTION DR. RASHMI SINGH, MD Assistant Professor, Department Of Pharmacology, Shri Ram Murti Smarak Institute Of Medical Sciences, Bareilly, UP, 243202 Phone No.-9451380973 Normal sight depends on a moist ocular surface and this moisture is maintained by a complex interplay of various factors like sufficient quantity of tears, normal composition of tear film, normal lid closure and regular blinking of lids. Dry eye syndrome (DES) -- also known as dry eye or keratoconjunctivitis sicca (KCS) -- is a common disorder of the tear film that affects a significant percentage of the population, especially those older than 40 years of age. It is characterized by a disturbance of the tear film in which eye is unable to maintain a healthy layer of tears to coat it. This abnormality may result in disruption of the ocular surface and various changes like squamous metaplasia, epithelial defects and infections of corneal epithelium causing a variety of symptoms and signs which interfere with quality of life. So tear film is very important in the maintenance of an intact ocular surface and thus pathologies of the conjunctival and corneal epithelium are intimately related to tear film dysfunction (Mahajan, 2009).

Three main layers make up this tear film. Innermost layer is mucin, middle is aqueous and the most superficial layer is of lipids. Defects of the aqueous layer are the most common cause of dry eye syndrome. Various conventional treatments such as ocular surface lubrication with frequent instillation of artificial tears, protective glasses, and punctal occlusion provide benefit to the patients (Young et al, 2004). However despite maximal therapy many patients continue to have signs and symptoms of dry eye. That s why treatment of ocular disorders with biological fluids has also been advocated (Rocha et al, 2000). More recently, autologous serum (AS) tears have been indicated for the treatment of dry eye. The rationale for this is based upon the fact that vitamins and growth factors present in tears, are also present in serum but lacking in artificial tears (Fox et al, 1984, Tsubota et al, 1999). Therefore the present study was designed to evaluate the effectiveness of the autologous serum eyedrops in relieving the symptoms and objective improvement in patients of dry eye. MATERIALS & METHOD The present prospective study was conducted in Department of Ophthalmology and Pharmacology, Shri Ram Murti Smarak Institute of Medical Sciences, Bareilly, from 16.07.11 to 16.03.12 (six months). The study included 34 eyes of 20 patients with dry eye disorder who used autologus serum eye drops along with artificial tears. Criteria for patient selection The study included the patients who satisfied the following criteria:- (1) Symptoms of dry eyes. (2) Break up time (BUT) <5 seconds & schirmer s test without anesthesia <5mm at 5 minutes. (3) Presence of Rose Bengal test and Fluorescin staining of ocular surface Criteria for patient exclusion Patients were not started on serum eye drops if patients have any of the following. (1)Patient with active microbial infection (acute herpes simplex/herpes zoster keratitis). (2)Vitamin A deficiency. (3)Progressive corneal melting due to any immunological process. (4)Recurrent corneal erosion syndrome. (5)Pregnant/ Lactating women. (6)Patient in whom venesection was not possible Preparation of autologous serum A total of 40 ml blood was taken by venepuncture from each patient under all aseptic precaution & collected in a sterile container. Blood was centrifuged at 4000rpm for 10 minutes. After separation of serum, it was packed into sterile dropper bottle preloaded with 3 ml unpreserved chloramphenicol (0.5% chloramphenicol with 1.5% boric acid, 0.3% borax and purified water) or 3 ml saline. If 100% serum is desired, saline or chloramphenicol is not used. 6 ml of 100% serum or 6 ml of 50% serum eye drops were dispensed to the patients. Patients were asked to keep the bottle in dark to prevent the degradation of vitamin A and the bottle in use should be kept at home refrigerator at 5 0 C up to 1 month and -20 0 C up to 3 months. Each bottle was discontinued after 7 days of use (Fox et al, 1984, Tsubota et al, 1999). Application of autologous serum Patient was asked to apply autologous serum 8-10 times per day and examined weekly for two weeks and then two weeks interval for their subjective and objective scores which determine the efficacy of the treatment. Weaning of serum drops was done in patients who have beneficial effect and continued if there was any worsening of symptoms after withdrawal of serum drops. Evaluation of patients Evaluation of patients were done before as well as after initiation of treatment in follow up, by determining the subjective and objective scores. Subjective evaluation was done by the following grading method:-0 no symptoms, 1- mild symptoms with no discomfort, 2- moderate symptoms with discomfort but no interference with daily activities, 3- severe symptoms with discomfort but no interference with daily activities, 4- very severe symptoms with discomfort and interference with daily activities. Objective scores included ocular surface evaluation by double staining method according to the scoring system suggested by National Eye Institute Workshop On Dry Eye. Rose Bengal staining (score 0 18) was used for bulbar conjunctival damage and flourescein staining (score 0 15) for corneal damage. Two μl of preservative-free solution consisting of 1% rose bengal and 1% fluorescein dye were applied to the conjunctival sac (Toda et al, 1993). The intensity of rose bengal staining was recorded in the temporal and nasal conjunctiva and the cornea, each graded on a scale of 0 to 3 points. Thus, the maximum score obtained from the staining of one eye is 9. Fluorescein staining was also rated from 0 to 9, but only in the cornea. Score of 3 or more for both the staining was the cut of value for diagnosis of dry eye disease. OBSERVATIONS The observations were based on the finding of dry eyes of same patients who used autologous serum along with artificial tears and were tabulated into 3 groups. GROUP A- Observation before the use of autologous serum. GROUP B- Observation after the use of autologous serum at 1 month. GROUP C- Observation after the use of autologous serum at 2 months. Patients were analyzed regarding: age, sex, subjective score and objective score (rose bengal & flourscein staining).

AGE DISTRIBUTION 8 7 6 5 No of patients 4 3 2 1 0 10--19 20-29 30-39 40-49 50-59 >60 Age group(years) Fig. 1: Distribution of patients according to age. Table. 1: Subjective Scores before and after use of autologus serum. Subjective Score Group A Observation before use of autologous serum Group B Observation after use of Group C Observation after use of autologous serum at 2 months 4 20(58.82%) 6(17.64%) - 3 11(32.35%) 8(23.52%) 02(7.14%) 2 03(8.82%) 20(58.82%) 24(85.71%) 1 - - 02(7.14%) 0 - - - Table. 2: Objective Scores (Fluorescin staining score) before and after use of autologus serum. Fluorescin Staining Group--A Observation before use of Group --B Observation after use of Group C Observation after use of Scores autologous serum autologous serum at 2 months 0 3 - - 01(3.6%) 4 6 01(2.94%) 13(38.83%) 27(96.4%) 7 9 18(52.9%) 16(47.05%) - 10 12 15(44.1%) 5(14.70%) - 13--15 - - - TABLE. 3 :- Objective (rose bengal staining)scores before and after use of autologus serum Rose Bengal Staining Scores Group--A Observation before use of autologous serum Group --B Observation after use of Group C Observation after use of autologous serum at 2 months 3--6 01(2.95%) 6(17.64%) 13(46.42%) 7--10 10(29.54%) 17(50%) 15(53.50%) 11--14 23(67.6%) 11(32.35%) - 15--18 - - - RESULTS The present study included 34 eyes of 20 patients having dry eye disorder. Out of these 20 patients, 16(80%) were males and 4 (20%) were females with a male female ratio of M : F - 4 :1. Distribution of patients according to age is shown in Figure. 1 which shows that the maximum number of patients belongs to age group of >60 years and the mean age of the patient is 51.95 years. Regarding the subjective scores (Table.1), it was maximum in group A and least in group C. In group C, out of 34, 28 eyes (82.36%) show decrease in subjective score but 6 eyes (17.64%) show no response to autologus serum at follow up of 2 months as they stopped the drops after one month of use because of discomfort. The results of objective scores were similar to subjective scores. Fluorescein staining score (Table.2) and Rose Bengal staining score (Table.3) both were maximum in group A and lower in group C. Again a total of only 28 eyes (82.36%) show decrease in Fluorescein and Rose Bengal staining score and 6 eyes(17.64%) did not show any improvement at follow up of 2 months as they stopped the drops after one month of use because of discomfort.

DISCUSSION Dry eye syndrome is a common clinical entity causing discomfort to many people (Pokupec et al, 2005). Standard substitution therapy with artificial tears like hydroxypropyl methyl cellulose and carboxymethylcellulose are effective in providing lubrication to the ocular surface, but are unable to substitute the nutrients and factors present in natural tears (Mahajan, 2009). This is why autologus serum come into focus, which contain various factors that are also present in natural tears. These factors include vitamin A, epidermal growth factor (EGF), transforming growth factor beta (TGF β), basic fibroblast growth factor, insulin like growth factor, substance P as well as proteins such as lactoferrin and lysozyme etc. (Rocha et al, 2000). Vitamin A plays a vital role in reducing the progress to squamous metaplasia in dry eye (Mahajan, 2009). EGF has been found to be helpful in healing of epithelial abrasions and it also facilitates epithelialisation because of its anti-apoptotic properties (Scardovi et al, 1993, Pastor and Calonge, 1992, Collins et al, 1994, Rodeck et al, 1997). Similarly transforming growth factor beta is also believed to control epithelial proliferation and to maintain cells in an undifferentiated state. Acidic and basic fibroblast growth factors (afgf, bfgf) are also found to speed up healing of epithelial defects (Fredj- Reygrobellet et al, 1987). Serum has also been shown to accelerate the migration of corneal epithelial cells in vitro; with upregulation of mucin expression and this may have beneficial effect in dry eye patient (Tsubota et al, 1999). Neural factors such as substance P are important for corneal epithelial migration. Serum also contains antiproteases such as beta-2 macroglobulins which has been thought to inhibit corneal collagenase and therefore, beneficial in conditions like alkali burns (Young et al, 2004). Proteins are also present in high concentration in serum, pre-albumin acts as a stabilizer for tear film and hence are important in the maintenance of its stability. Thus the rationale behind using autologus human serum in eye is that it contains the same growth factors that are present in tears. As a consequence it is now possible to create eye drops from the blood sample collected from the individual with dry eye. Furthermore serum also contains IgG, lysozyme and complement all of which may serve to additional antiinfective properties to a compromised surface. In this present study 34 eyes of 20 patients were examined for the evaluation of efficacy of autologus serum and patients were analyzed regarding age, sex, subjective score and objective score. The study showed that the maximum number of patients belonged to age group of >60 years and the mean age of the patient was 51.95 years. The results correspond to the study of Poon et al, 2001, who found that dry eye disease was frequent in individual above 50 years of age pointing towards aging and postmenopausal causes. This may be because of aqueous layer abnormality. Regarding the sex distribution, in our study M: F ratio was 4:1 but we didn t find any study, showing any sex preponderance. Subjective score was based on the grading of symptoms as mentioned above. The score was least in group C in which 28 eyes (82.36%) showed decrease in subjective score but 6 eyes (17.64%) did not show response to autologus serum at follow up of 2 months as they stopped the drops after one month of use because of discomfort. Our finding were consistent with the study of fox et al, 1984 and Tsubota et al, 1999, who found decrease in subjective as well as objective scores by the use of autologus serum diluted to 30% and 20% in saline respectively. The objective scores were measured by Rose Bengal staining and fluorescin staining. Normally rose Bengal is a water soluble dye that stains degenerated and dead cells as well as mucous fibrils. The stain produce a punctuate coloration along the lacrimal revus. Current understanding for Rose Bengal staining of ocular surface is due to loss of normal mucin layer in dry eye disease, allowing the dye to stain live epithelial cells that would normally be protected by mucin in healthy eyes. Recent researches have suggested that staining in dry eye is associated with a altered glycosylation of the surface mucin of apical conjuctival cells. Thus although stained cells are not necessarily degenerated, they may suffer from impaired expression of membrane mucin. Impression cytology studies also suggest that autologus serum leads to upregulation of goblet and mucin expression in dose dependent manner. Fluorescein is a water soluble dye that can be excited by illumination with near ultraviolet light such as that produced by cobalt blue filters. In dry eye patients, fluorescein accumulates in the intracellular spaces resulting from discontinuity in the corneal epithelium. The thickness in the tear film and its integrity can be assessed by the intensity of the coloration over the ocular surface. Patients with reduced tear volume or tear film thickness usually exhibit a less intense fluorescence despite good illumination. In this study both rose bengal staining as well as fluorescein staining were least in group C and maximum in group A after 2 months of treatment. Thus the objective scores were improved by the use of autologus serum. Our findings were consistent with the study of fox et al, 1984 and Tsubota et al, 1999, as mentioned above. The results were similar to the studies of Kojima et al, 2005, who compared the artificial tears and autologus serum in dry eye patients and found that there was significant improvement in tear film break up time, subjective score, fluorescein and rose bengal staining in patients assigned to autologus serum. The results also correspond with the study of Creuzol et al, 2004, who applied the 20% autologus serum in eyes of sjogren s syndrome and found to be very effective in improving fluorescein staining as well as subjective symptoms of burning, foreign body sensation and dryness. Poon et al, 2001, recently also reported their experiences using 20% autologous serum drops to treat 11 dry eyes of 9 patients with KCS, and noted 60% improvement based on fluorescein, rose bengal staining and subjective symptoms score. In contrast, study done by Goto et al, 2001, recommended that autologous serum should only be considered as a second choice only if punctal occlusion is not effective. They treated 11 patients with superior limbic keratoconjunctivitis with 20% autologous serum drops for 4 weeks, and noted partial efficacy in 82% of them using the fluorescein and rose bengal staining as well as subjective symptom score. They also pointed out in the study that autologous serum drops might also provide lipids, a very

important component of the tear, but did not perform any measure of lipid components. Besides this in our study 6 eyes showed no response to autologus serum at follow up of 2 months who stopped the drops after one month of use because of discomfort on instillation of autologus serum eye drops. CONCLUSION Autologous serum drops were found to be effective in improvement of symptoms and objective signs in severe dry eye disorder. The drawbacks of this treatment is to obtain blood from patients. Thus, the development of an ideal artificial tear substitute containing these essential components would be ideal. But until such medication is available, the use of autologous serum may be of great benefit for the dry eye patients. ACKNOWLEDGMENT We would like to express our gratitude to Mr. Dev Murti, Chairman, SRMS Institute of Medical Sciences, Bareilly for his encouragement for research work as well as to all the patients for their kind cooperation. CONFLICT OF INTERESTS The authors declare that there is no conflict of interest to disclose REFERENCES Collins M.K., Perkins G.R., Rodriguez T.G., et al. Growth factors as survival factors: regulation of apoptosis. Bioassays 1994; 16:133 138. Creuzot G.C., Lafontaine P.O., Brignole F., Pisella P.J., D'Athis P., Bron A., Lapierre V., Baudouin C. Treating severe dry eye syndromes with autologous serum. J Fr Ophtalmol 2004 ; 27(4): 346-351. Fox R.I., Chan R., Michelson J.B., et al. Beneficial effect of artificial tears made with autologous serum in patients with keratoconjunctivitis sicca. Arthr Rheum 1984; 27: 459 461. Fredj-Reygrobellet D., Plouet J., Delayre T., et al. Effects of afgf and bfgf on wound healing in rabbit corneas. Curr Eye Res 1987; 6:1205 1209. Goto E., Shimmura S., Shimazaki J., Tsubota K. Treatment of superior limbic keratoconjunctivitis by application of autologous serum. Cornea 2001; 20: 807-810. Kojima T., Ishida R., Dogru M., Goto E., Matsumoto Y., Kaido M., Tsubota K. The effect of autologous serum eyedrops in the treatment of severe dry eye disease: a prospective randomized case-control study. Am J Ophthalmol 2005; 139(2): 242-246. Mahajan P.S. Autologous serum in eye disorders. JK Science 2009; 11(3): 111-113. Pastor J.C., Calonge M. Epidermal growth factor and corneal wound healing: a multicenter study. Cornea 1992; 11: 311 314. Pokupec R., Petricek I., Sikić J., Bradić M., Popović-Suić S., Petricek G. Comparison of local acetylcysteine and artificial tears in the management of dry eye syndrome. Acta Med Croatica. 2005; 59(4):337-340. Poon A.C., Geerling G., Dart J.K., et al. Autologous serum eyedrops for dry eyes and epithelial defects: clinical and in vitro toxicity studies. Br J Ophthalmol 2001; 85:1188-1197. Rocha E.M., Pelegrino F.S.A., DePaiva C.S., Vigorito A.C., DeSouza C.A. GVHD dry eyes treated with autologous serum tears. Bone Marrow Transplantation 2000; 25: 1101 1103. Rodeck U, Jost M, Kari C, et al. EGF-R dependent regulation of keratinocyte survival. J Cell Sci 1997;110:113 21 Scardovi C., De Felice G.P., Gazzaniga A. Epidermal growth factor in the topical treatment of traumatic corneal ulcers. Ophthalmologica 1993; 206:119 124. Toda I., Tsubota K. Practical double vital staining for ocular surface evaluation. Cornea 1993; 12: 366 367. Tsubota K., Goto E., Shimmura S., et al. Treatment of persistent corneal epithelial defect by autologous serum application. Ophthalmology 1999;106:1984-1989. Tsubota K., Goto E., Fujita H., et al. Treatment of dry eye by autologous serum application in Sjogren s syndrome. Br J Ophthalmol 1999; 83: 390 395. Young A.L., Cheng A.C.O., Ng H.K., Cheng L.L., Leung G.Y.S., Lam D.S.C. The use of autologous serum tears in persistent corneal epithelial defects. Eye 2004; 18: 609 614.